Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Frequently Asked Questions: 1
BPC 157 is not FDA approved to treat ulcerative colitis, Crohn's disease, IBS, or any other medical condition in humans
GHK-Cu is administered via subcutaneous injection for systemic effects or applied topically in dermatological research
In initial preclinical studies, orforglipron has been shown to stimulate insulin secretion and reduce food consumption in non-human primates, and it is fully efficacious at lowering hyperglycemia in mice expressing the human GLP-1R but inactive in GLP-1R knockout animals
The naming convention reflects the mechanistic story rather than any cosmetic marketing claim: GHK-Cu and TB-500 are widely cited in dermal and connective-tissue repair literature, while BPC-157 brings vascular and gastrointestinal models to the same vial
US$ 22.35
US$ 24.88
US$ 26.61
US$ 23.13
US$ 28.22
US$ 25.25
US$ 29.97
